Filter
440
Filtered Results: 440
Text search:
National
Institute
for
Viral
Disease
Control
and
Prevention,
China
Featured
Recommendations
61
New Publications
64
Language
Document type
No document type
157
Guidelines
129
Studies & Reports
82
Manuals
31
Strategic & Response Plan
18
Fact sheets
11
Situation Updates
5
Training Material
4
Resource Platforms
2
Infographics
1
Countries / Regions
Global
19
India
15
South Africa
13
Brazil
10
Western and Central Europe
10
Latin America and the Carribbean
8
Africa
8
Germany
7
Russia
7
Vietnam
6
Kenya
5
Mozambique
5
Peru
4
Colombia
4
Ecuador
4
Bolivia
4
Angola
4
West and Central Africa
4
Eastern Europe and Central Asia
4
Asia
4
Spain
4
Guinea-Bissau
3
Uganda
3
Syria
3
China
3
Ukraine
3
Myanmar / Burma
3
East and Southern Africa
3
Eastern Europe
3
Portugal
3
Guinea
2
Ethiopia
2
Pakistan
2
Bangladesh
2
Papua New Guinea
2
Namibia
2
Venezuela
2
Laos
2
France
2
Sierra Leone
1
Liberia
1
Congo, Democratic Republic of
1
Ghana
1
Zimbabwe
1
South Sudan
1
Jordan
1
Turkey
1
Tanzania
1
Cambodia
1
Thailand
1
Malawi
1
Sudan
1
Central African Republic
1
Argentina
1
North Macedonia
1
Honduras
1
Botswana
1
El Salvador
1
Mexico
1
Chile
1
Yemen
1
Middle East and North Africa
1
South–East Asia Region
1
Western Pacific Region
1
Paraguay
1
Albania
1
North America
1
Mauritius
1
United Kingdom
1
Authors & Publishers
Publication Years
Category
Countries
116
Clinical Guidelines
62
Public Health
18
Women & Child Health
9
Key Resources
8
Pharmacy & Technologies
7
Capacity Building
2
Toolboxes
COVID-19
142
HIV
77
Rapid Response
28
TB
19
AMR
17
Mental Health
15
Planetary Health
15
Ebola
10
Global Health Education
9
NCDs
8
Refugee
7
NTDs
7
Specific Hazards
5
Disability
4
Pharmacy
4
Polio
3
Conflict
2
Natural Hazards
2
Zika
2
Health Financing Toolbox
2
Cholera
1
Health Financing
1
International Journal of Infectious Diseases 32 (2015) 170–178
http://dx.doi.org/10.1016/j.ijid.2014.11.023
1201-9712/ß 2014 The Authors. Published by Elsevier Ltd on behalf of International Society ... Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Asthma is the commonest chronic childhood disease and encompasses a spectrum of airway diseases with similar symptoms. Inaccurate diagnosis remains...
Updated recommendations on treatment of adolescents and children with chronic HCV infection
recommended
The new treatment recommendations that extend the 2018 treat all recommendation for adults with chronic HCV infection to include adolescents and children down to 3 years, ... to align the existing recommended pangenotypic direct-acting antiviral (DAA) regimens (SOF/DCV, SOF/VEL and G/P) for adults, to those for adolescents and children. This alignment is expected to simplify procurement, promote access to treatment among children in low- and middle-income countries and contribute to global efforts to eliminate the disease
The National Disaster Management Plan (NDMP) provides a framework and direction to the government agencies for all phases of disaster management cy...
Laboratory biosafety guidance related to coronavirus disease (COVID-19): Interim guidance, 28 January 2021
recommended
The latest update (28 January 2021) includes the following addition and revision:
biosafety aspects for working with antigen-detecting rapid diagnostic test;
handling new variants of SAR...
The threat posed by antimicrobial resistance (AMR) to public health as well as global health security has been reiterated in umerous World Health Assembly (WHA) resolutions. AMR is also prioritized under the Global Health Security Agenda (GHSA), and...
In Vietnam, most of the examination and treatment facilities are facing with of spread of bacteria resistant to many antibiotics. The level and speed of drug resistance are increasing, at alarming l...
On 17 October 2017, the Ugandan Ministry of Health notified WHO of a confirmed Marburg outbreak of Marburg Virus disease (MVD) in Kween district, Eastern Uganda. The outbreak was officially declared by the Ministry of health on 19 October 2017.
As ...
Development of one or more vaccines for Neisseria gonorrhoeae is an important objective for sexual and reproductive health worldwide, ... for the fight against antimicrobial resistance.
WHO preferred product characteristics (PPCs) provide strategic guidance as to WHO’s preferences for new vaccines in priority disease areas. PPCs are intended to encourage innovation and development of vaccines for use in settings most relevant to the global unmet public health need.
Gonococcal vaccine PPCs describe global public health goals for gonococcal vaccines and preferred parameters pertaining to vaccine indications and target populations, safety and efficacy considerations, and immunization strategies.
Overcoming barriers in low- and middle-income countries
For the first time, this year’s report includes information on hepatitis C diagnostics. With a focus on selected countries with diverse HCV...
9 March 2022, Timely and accurate diagnostic testing for SARS-CoV-2 is an essential part of a comprehensive COVID-19 response strategy. Ag-RDTs can be performed by individuals in which they collect ...
8 January 2021
Sequencing enabled the world to rapidly identify SARS-CoV-2 and develop diagnostic tests and other tools for outbreak management. C...
This manual addresses all the issues. It focus on the cycle of microbes, antibiotics, vaccination, AMR,
infection prevention and control. It will ...
Terminology used to describe the transmission of pathogens through the air varies across scientific disciplines, organizations and the general public. While this has been the case for decades, durin...
N95 or equivalent respirators are single-use personal protective equipment (PPE) designed for use by health workers that provide direct care to patients with diseases transmitted by aerosols or duri...
Constituting the second part of the World Drug Report 2022, the present booklet contains an overview of the global demand for and supply of drugs.
The first chapter of the booklet begins with the l...
A living WHO guideline on drugs for covid-19
recommended
BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3379
Rapid Recommendation and visual graph. This is the fifth version (update 4) of the living guideline (BMJ 2020;370:m3379). When citing this article, please consider adding the update number ... date of access for clarity. The publication of the RECOVERY and REMAP-CAP randomised controlled trials triggered this guideline update, resulting in a strong recommendation for interleukin-6 (IL-6) receptor blockers (tocilizumab or sarilumab) in patients with severe or critical covid-19.
Prior recommendations: (a) A recommendation not to use ivermectin in patients with covid-19, regardless of disease severity, except in the context of a clinical trial; (b) a strong recommendation against the use of hydroxychloroquine in patients with covid-19, regardless of disease severity; (c) a strong recommendation against the use of lopinavir-ritonavir in patients with covid-19, regardless of disease severity; (d) a strong recommendation for systemic corticosteroids in patients with severe and critical covid-19; (e) a conditional recommendation against systemic corticosteroids in patients with non-severe covid-19; and (f) a conditional recommendation against remdesivir in hospitalised patients with covid-19.
WHO Technical Series 971
The following protocol has been designed to investigate the First Few X cases (FFX) and their close contacts. It is envisioned that the FFX 2019-nCoV investigation will be conducted across several countries or sites with geographical ... demographical diversity. Using a standardized protocol such as the protocol provided here, epidemiological exposure data and biological samples can be systematically collected and shared rapidly in a format that can be easily aggregated, tabulated and analyzed across many different settings globally for timely estimates of 2019-nCoV infection severity and transmissibility, as well as to inform public health responses and policy decisions. This is particularly important in the context of a novel respiratory pathogen, such as 2019-nCoV
